Anti-VEGF monotherapy useful option in patients with RAP

Article

Anti-VEGF monotherapy appears to be an effective treatment for retinal angiomatous proliferation, according to results of a small, retrospective chart review. Although the results indicate that in most cases repeated injections would be needed to achieve improvement of stable vision, treatment based on ocular coherence tomography-confirmed presence of fluid could achieve outcomes similar to monthly injections.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
Related Content
A person in a lab coat holds a test tube full of fluid. They enter data onto a laptop. Image credit: ©Parichat – stock.adobe.com

Finnish researchers report on registry data and changing workload resulting from anti-VEGF therapies

Lynda Charters
December 24th 2024
Article

The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person in a business suit holds a lit-up lightbulb. Image credit: ©kamiphotos – stock.adobe.com

EssilorLuxottica announces agreement for acquisition of Espansione Group

Sydney M Crago
December 17th 2024
Article

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A gloved hand holds two syringes full of fluid. Image credit: ©StudioLaMagica – stock.adobe.com

European Medicines Agency approves faricimab (Vabysmo) 6.0 mg single-dose prefilled syringe

Hattie Hayes
December 13th 2024
Article

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion

A person's hand touches a digital output of a chart with several different data sets represented. Image credit: ©WrightStudio – stock.adobe.com

Investigators report findings on serum inflammatory biomarkers in patients with macular oedema

Lynda Charters
December 12th 2024
Article

A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO

© 2024 MJH Life Sciences

All rights reserved.